to 72 hours (48 hours)
NSAIDs may leads to lower to 72 hours (48 hours) compared with placebo (low certainty).
1 finding from 1 review
to 7 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events
It is very uncertain whether NSAIDs changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Mean time to resolution of pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean pain score at various time points
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reconsultations
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Delayed antibiotic prescriptions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
hours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participant‐reported pain relief of 50% or greater · acute gout
NSAIDs may leads to higher pain: ≥ 50% improvement in pain (spontaneous pain at 24 hours) compared with placebo (low certainty).
1 finding from 1 review
RR 2.75 [1.13, 6.72]
Studies not reported
Low
Inflammation: participants with no swelling at 72 hours (canakinumab 150 mg) Assessed by the investigator as no swelling, mild/palpable, moderate/visible, severe/bulging beyond the joint margins · acute gout
NSAIDs showed no clear difference in inflammation: swelling compared with placebo (low certainty).
1 finding from 1 review
RR 1.08 [0.79, 1.49]
Studies not reported
Low
Function: ≥ 50% improvement in pain with movement at 24 hours · acute gout
NSAIDs showed no clear difference in function: ≥ 50% improvement in pain with movement at 24 hours compared with placebo (low certainty).
1 finding from 1 review
RR 4 [0.5, 31.74]
Studies not reported
Low
Participants' global assessment of treatment: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Health‐related quality of life: not measured№. of participants: 30 (1 RCT) · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Withdrawals due to adverse events · acute gout
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Total adverse events · acute gout
NSAIDs showed no clear difference in total adverse events compared with placebo (low certainty).
1 finding from 1 review
RR 0.2 [0.01, 3.85]
Studies not reported
Low
Pain intensity VAS (0 to 100; 0 = no pain, 100 = worst pain) · Patients with acute low‐back pain
1 finding from 1 review
Disability RMDQ (0 to 24; lower = better) · Patients with acute low‐back pain
1 finding from 1 review
Proportion of participants experiencing global improvement % of dichotomized Likert scale · Patients with acute low‐back pain
NSAIDs may leads to higher proportion of participants experiencing global improvement Various… compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes proportion of participants experiencing adverse events compared with placebo (very low certainty).
1 finding from 1 review
Return to work · Patients with acute low‐back pain
It is very uncertain whether NSAIDs changes return to work (%) compared with placebo (very low certainty).
1 finding from 1 review